Patents by Inventor Jean-Frederic Colombel

Jean-Frederic Colombel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210252141
    Abstract: The invention features new a method for treating inflammatory bowel disease, including Crohn's Disease (CD) or ulcerative colitis in a human patient, comprising administering to a patient a combination therapy comprising an anti-?4?7 antibody, a TNF? antagonist, and an immunomodulator.
    Type: Application
    Filed: January 19, 2021
    Publication date: August 19, 2021
    Inventors: Trevor Warren Lissoos, Jean-Frederic Colombel
  • Patent number: 10918716
    Abstract: The invention features new a method for treating inflammatory bowel disease, including Crohn's Disease (CD) or ulcerative colitis in a human patient, comprising administering to a patient a combination therapy comprising an anti-?4?7 antibody, a TNF? antagonist, and an immunomodulator.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: February 16, 2021
    Assignees: Millennium Pharmaceuticals, Inc., Icahn School of Medicine at Mount Sinai
    Inventors: Trevor Warren Lissoos, Jean-Frederic Colombel
  • Publication number: 20190142938
    Abstract: The invention features new a method for treating inflammatory bowel disease, including Crohn's Disease (CD) or ulcerative colitis in a human patient, comprising administering to a patient a combination therapy comprising an anti-?4?7 antibody, a TNF? antagonist, and an immunomodulator.
    Type: Application
    Filed: May 4, 2017
    Publication date: May 16, 2019
    Inventors: Trevor Warren Lissoos, Jean-Frederic Colombel
  • Patent number: 9593313
    Abstract: The present invention relates to a product selected from a protein, a fragment of the protein, a derived sequence and a homologous sequence of the protein, the protein including or being constituted by the 28 kDa glutathione S-transferase protein from a schistosome selected from Schistosoma haematobium, Schistosoma mansoni, Schistosoma bovis represented respectively by the sequences SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3 for the use thereof in the treatment of an inflammatory autoimmune disease generating a response of type Th1 and/or Th17.
    Type: Grant
    Filed: February 6, 2013
    Date of Patent: March 14, 2017
    Assignees: UNIVERSITE DU DROIT ET DE LA SANTE DE LILLE 2, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE LILLE
    Inventors: Monique Capron, Mohamed El Nady, Jean-Frederic Colombel, Gilles Riveau
  • Publication number: 20150118259
    Abstract: The present invention relates to a product selected from a protein, a fragment of the protein, a derived sequence and a homologous sequence of the protein, the protein including or being constituted by the 28 kDa glutathione S-transferase protein from a schistosome selected from Schistosoma haematobium, Schistosoma mansoni, Schistosoma bovis represented respectively by the sequences SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3 for the use thereof in the treatment of an inflammatory autoimmune disease generating a response of type Th1 and/or Th17.
    Type: Application
    Filed: February 6, 2013
    Publication date: April 30, 2015
    Applicants: UNIVERSITE DU DROIT ET DE LA SANTE DE LILLE 2, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE LILLE
    Inventors: Monique Capron, Mohamed El Nady, Jean-Frederic Colombel, Gilles Riveau
  • Publication number: 20060270627
    Abstract: A pharmaceutical composition including a therapeutically effective amount of at least one oligomannoside produced by chemical synthesis which is homologous to a wall oligomannoside of an infectious organism or pathogen, or a derivative thereof, and a pharmaceutically acceptable vehicle.
    Type: Application
    Filed: August 1, 2006
    Publication date: November 30, 2006
    Applicant: Centre Hospitalier regional universitaire (CHRU)
    Inventors: Jacques Esnault, Pierre Sinay, Reynald Chevalier, Jean-Frederic Colombel, Jean-Maurice Mallet, Boualem Sendid, Thierry Jouault, Daniel Poulain, Pierre-Andre Trinel
  • Patent number: 7109182
    Abstract: A pharmaceutical composition including a therapeutically effective amount of at least one oligomannoside produced by chemical synthesis which is homologous to a wall oligomannoside of an infectious organism or pathogen, or a derivative thereof, and a pharmaceutically acceptable vehicle.
    Type: Grant
    Filed: May 23, 2002
    Date of Patent: September 19, 2006
    Assignee: Centre Hospitalier Regional Universitaire (CHRU)
    Inventors: Jacques Esnault, Pierre Sinay, Reynald Chevalier, Jean-Frédéric Colombel, Jean-Maurice Mallet, Boualem Sendid, Thierry Jouault, Daniel Poulain, Pierre-André Trinel
  • Publication number: 20060051353
    Abstract: The present invention relates to methods and compositions to evaluate or assess the response of a subject to particular therapeutic treatment. More particularly, the invention provides methods to determine the response of subjects, or to adapt the treatment protocol of subjects treated with therapeutic antibodies. The invention is based on a determination of the FCGR3A genotype of a subject. The invention can be used for patients with malignancies, particularly lymphoma, and is suited to select best responders and/or adjust treatment condition or protocol for low responders.
    Type: Application
    Filed: May 13, 2005
    Publication date: March 9, 2006
    Inventors: Jean-Frederic Colombel, Herve Watier, Edouard Louis
  • Publication number: 20040132110
    Abstract: The invention relates to a method for the in vitro diagnosis of chronic intestinal inflammatory diseases, such as Crohn's disease or haemorrhagic rectal colitis. The invention also relates to the use of compounds, such as an antibody, ligand or nucleic probe capable of specifically recognising PPAR&ggr; gene expression products, for the preparation of the composition or kit for diagnosing said diseases.
    Type: Application
    Filed: February 26, 2004
    Publication date: July 8, 2004
    Inventors: Pierre Desreumaux, Jean Frederic Colombel, Laurent Dubuquoy
  • Publication number: 20030105060
    Abstract: A pharmaceutical composition including a therapeutically effective amount of at least one oligomannoside produced by chemical synthesis which is homologous to a wall oligomannoside of an infectious organism or pathogen, or a derivative thereof, and a pharmaceutically acceptable vehicle.
    Type: Application
    Filed: May 23, 2002
    Publication date: June 5, 2003
    Applicant: Centre Hospitalier Regional Universitaire (CHRU)
    Inventors: Jacques Esnault, Pierre Sinay, Reynald Chevalier, Jean-Frederic Colombel, Jean-Maurice Mallet, Boualem Sendid, Thierry Jouault, Daniel Poulain, Pierre-Andre Trinel